losartan has been researched along with Diabetic Cardiomyopathies in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan has a protective effect on heart function against myocardial interstitial fibrosis of DCM by inhibiting JAK/STAT signaling pathway and lowering the expression of TGF-β1." | 1.42 | Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. ( Li, D; Li, J; Wang, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castoldi, G | 1 |
| di Gioia, CRT | 1 |
| Roma, F | 1 |
| Carletti, R | 1 |
| Manzoni, G | 1 |
| Stella, A | 1 |
| Zerbini, G | 1 |
| Perseghin, G | 1 |
| Wang, L | 1 |
| Li, J | 1 |
| Li, D | 1 |
2 other studies available for losartan and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Di | 2019 |
Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Cardiomyopathies; Endomyocardial Fibrosis | 2015 |